OverviewSuggest Edit
Abiomed is a company providing medical devices for circulatory support. It offers Impella, a small heart pump designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. Abiomed also provides clinical and product information, from professional resources to video training.
| Type | Public | |
| Founded | 1981 | |
| HQ | Danvers, MA, US | Map |
| Website | abiomed.com | |
| Employee Ratings | More | |
| Overall Culture | C- | More |
Recent NewsAll News
Key People/Management at Abiomed
Michael R Minogue
Marc A Began
William J Bolt
Andrew J Greenfield
Laxmi Peri
Karen Mahoney
Abiomed Office Locations
Abiomed Financials and Metrics
Abiomed Revenue
| USD | |
|---|---|
Revenue (Q3, 2021) | 231.7m |
Gross profit (Q3, 2021) | 190.6m |
Gross profit margin (Q3, 2021), % | 82.3% |
Net income (Q3, 2021) | 61.9m |
EBIT (Q3, 2021) | 71.4m |
Market capitalization (25-Jan-2022) | 14.2b |
Closing stock price (25-Jan-2022) | 296.8 |
Cash (31-Dec-2020) | 181.0m |
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 103.0m | 103.0m | 114.7m | 132.5m | 132.8m | 154.0m | 180.0m | 181.8m | 200.6m | 207.7m | 205.0m | 221.6m | 164.9m | 209.8m | 231.7m |
Cost of goods sold | 15.1m | 17.3m | 19.0m | 21.9m | 21.6m | 25.0m | 30.9m | 29.8m | 34.0m | 37.1m | 34.9m | 40.0m | 36.0m | 38.7m | 41.1m |
Gross profit | 87.9m | 85.6m | 95.7m | 110.6m | 111.2m | 129.0m | 149.2m | 151.9m | 166.5m | 170.6m | 170.1m | 181.6m | 128.9m | 171.0m | 190.6m |
Gross profit Margin, % | 85% | 83% | 83% | 83% | 84% | 84% | 83% | 84% | 83% | 82% | 83% | 82% | 78% | 82% | 82% |
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 38.3m | 54.7m | 61.1m | 44.0m | 44.5m | 50.5m | 61.3m | 76.4m | 84.2m | 101.0m | 150.3m | 118.0m | 214.8m | 202.2m | 181.0m |
Accounts Receivable | 41.3m | 46.6m | 50.2m | 53.6m | 57.3m | 64.9m | 67.5m | 74.2m | 88.2m | 86.2m | 94.3m | 101.0m | 82.1m | 80.9m | 93.0m |
Prepaid Expenses | 6.7m | 8.8m | 10.5m | 9.0m | 9.0m | 9.2m | 13.5m | 13.3m | 10.5m | 16.8m | 17.5m | 16.9m | 21.0m | 19.4m | 31.8m |
Inventories | 29.1m | 31.5m | 32.1m | 36.9m | 40.6m | 46.9m | 55.8m | 63.7m | 71.8m | 87.7m | 90.3m | 91.2m | 89.3m | 83.2m | 82.4m |
| USD | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 12.9m | 21.8m | 37.2m | 37.4m | 61.9m | 75.3m | 90.1m | 140.2m | 185.1m | 88.9m | 102.0m | 171.2m | 44.6m | 106.8m | 168.7m |
Depreciation and Amortization | 1.4m | 3.0m | 4.5m | 2.5m | 5.3m | 8.1m | 3.0m | 6.3m | 9.9m | 4.4m | 9.1m | 14.4m | 5.5m | 11.1m | 17.3m |
Inventories | (3.4m) | (6.3m) | (8.6m) | (1.3m) | (5.4m) | (12.0m) | (7.8m) | (16.7m) | (26.5m) | (7.2m) | (12.2m) | (13.3m) | (211.0k) | 6.1m | 6.6m |
Accounts Payable | (145.0k) | 1.9m | 3.5m | (4.4m) | 299.0k | 2.6m | 2.7m | 761.0k | 4.9m | (1.5m) | 781.0k | 841.0k | (4.5m) | (10.1m) | (8.1m) |
| USD | Q1, 2017 |
|---|---|
Financial Leverage | 1.1 x |
Abiomed Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| ECP Entwicklungsgesellschaft mbH | July 01, 2014 | $13 m |
| Impella Cardiosystems | April 28, 2005 | |
| ABD Holding Company | ||
| ABIOMED Athlone Ltd | ||
| ABIOMED Australia Pte. Ltd | ||
| ABIOMED Europe | ||
| ABIOMED Japan KK | ||
| ABIOMED Limited | ||
| ABIOMED R&D | ||
| ABIOMED SARL |
Abiomed Revenue Breakdown
Abiomed revenue breakdown by business segment: 96.4% from Impella Product and 3.6% from Other
Abiomed revenue breakdown by geographic segment: 86.4% from US and 13.6% from International
Abiomed Cybersecurity Score
Abiomed Environment, Social & Governance (ESG) Ratings
Abiomed Online and Social Media Presence
4.12k Twitter followers
Abiomed has 4.12k Twitter Followers. The number of followers has increased 1.5% month over month and increased 3.5% quarter over quarter
Abiomed's Trends
Twitter Engagement Stats for @abiomedimpella
2.3k
Tweets
1.9k
Following
4.1k
Followers
27
Tweets last 30 days
7.6
Avg. likes per Tweet
92.6%
Tweets with engagement
Abiomed Company Culture
Overall Culture
C-
65/100
CEO Rating
D
60/100
Compensation
A-
80/100
Abiomed News and Updates
$4.8 Billion Cardiac Assist Devices Global Market to 2027 - Players Include Abiomed, Berlin Heart and Getinge Group Among Others
Here’s Why Abiomed Stock Is Attractive After A 20% Drop
Abiomed Is Up 60% This Year, Can The Rally Continue?
FDA approves Abiomed heart pump to treat coronavirus patients
FDA approves emergency use of Abiomed heart pump for COVID-19 patients
Abiomed gets emergency authorization to use heart pump in COVID-19 patients
Abiomed Frequently Asked Questions
When was Abiomed founded?
Abiomed was founded in 1981.
Who are Abiomed key executives?
Abiomed's key executives are Michael R Minogue, Marc A Began and William J Bolt.
How many employees does Abiomed have?
Abiomed has 1,371 employees.
What is Abiomed revenue?
Latest Abiomed annual revenue is $840.9 m.
What is Abiomed revenue per employee?
Latest Abiomed revenue per employee is $613.3 k.
Who are Abiomed competitors?
Competitors of Abiomed include Gerresheimer, Fresenius Kabi and Sopharma.
Where is Abiomed headquarters?
Abiomed headquarters is located at 22 Cherry Hill Dr, Danvers.
Where are Abiomed offices?
Abiomed has offices in Danvers, Boston, Aachen and Chuo City.
How many offices does Abiomed have?
Abiomed has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies